Long QT Syndrome Clinical Trial
Official title:
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Verified date | August 2019 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with corrected QT (QTc) interval prolongation. More than 50 commonly used drugs available on the US market may cause QTc interval prolongation and TdP. While TdP occurs more commonly in women, 33-45% of all cases of TdP have occurred in men. Older age is a risk factor for drug-induced TdP in men, possibly due to declining serum testosterone concentrations. Available evidence shows an inverse relationship between QTc intervals and serum testosterone concentrations. In addition, experimental data, including those from the investigators' laboratory, suggest that both exogenous testosterone or progesterone administration may be protective against prolongation of ventricular repolarization and TdP. Specific Aim: Establish the influence of transdermal testosterone administration and oral progesterone administration as preventive methods by which to diminish the degree of drug-induced QT interval prolongation in men 65 years of age or older. Hypothesis: Transdermal testosterone administration and oral progesterone administration both effectively attenuate drug-induced QT interval response in older men. To test this hypothesis, transdermal testosterone, oral progesterone or placebo will be administered in a 3-way crossover study to men 65 years of age or older. QTc interval response to low-dose ibutilide will be assessed. The primary endpoints will be Fridericia-corrected QT interval (QTF) response to ibutilide, in the presence and absence of testosterone, and in the presence or absence of progesterone: 1) Effect on pre-ibutilide QTF, 2) Effect on maximum post-ibutilide QTF, 3) Effect on % change in post-ibutilide QTF, and 2) Area under the QTF interval-time curves.
Status | Completed |
Enrollment | 14 |
Est. completion date | October 19, 2017 |
Est. primary completion date | October 19, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Men = 65 years of age Exclusion Criteria: - Prostate cancer; history of prostate cancer; - History of breast cancer; benign prostatic hypertrophy; - Weight < 60 kg - Weight > 135 kg - Serum k+ < 3.6 mEq/L; - Serum mg2+ < 1.8 mg/dL; - Hemoglobin < 9.0 mg/dL; - Hematocrit < 26%; - Hepatic transaminases > 3x upper limit of normal; - Baseline Bazett's-corrected QT interval > 450 ms - Heart failure due to reduced ejection fraction (left ventricular ejection fraction < 40%) - Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death; - Concomitant use of any QT interval-prolonging drug. |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University | American Heart Association, Purdue University |
United States,
Muensterman Tomaselli E, Sowinski KM, Jaynes HA, Overholser BR, Kovacs RJ, Tisdale JE. Transdermal testosterone administration attenuates drug-induced QT interval lengthening in older men. Circulation 2018;138:A15197.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) | QT interval is an electrocardiogram (ECG) measure of ventricular repolarization. Prolonged QT interval is a marker of increased risk of the ventricular arrhythmia known as torsades de pointes, which can cause sudden cardiac death. QT intervals were measured from ECG lead II by one investigator (E.T.M.) who was blinded to the subjects' assigned treatment phases. QT intervals were measured using computerized high-resolution electronic calipers (EP Calipers 1.6). QT and RR intervals at each time point were averaged over 3 consecutive complexes. The end of the T-wave was determined via the tangent method. Only clearly discernable QT intervals were measured. QT intervals vary with heart rate, and therefore must be corrected for heart rate. QT intervals were corrected using the Fridericia (QTF) method. The baseline QTF assesses the influence of testosterone and progesterone on naturally-occurring (before ibutilide administration) QTF | Following 7 days of testosterone, progesterone or placebo | |
Primary | Maximum QTF Following Ibutilide 0.003 mg/kg | QT interval is an ECG measure of ventricular repolarization. Prolonged QT interval is a marker of increased risk of the ventricular arrhythmia known as torsades de pointes, which can cause sudden cardiac death. Three 12-lead ECGs were obtained ~ 1 minute apart immediately at the end of the ibutilide infusion and at 5, 10, 15, 20, 30, and 45 minutes and 1, 2, 4, 6, and 8 hours post-infusion. QT intervals were measured from ECG lead II by one investigator (E.T.M.) who was blinded to the subjects' assigned treatment phases. QT intervals were measured using computerized high-resolution electronic calipers. QT and RR intervals at each time point were averaged over 3 consecutive complexes. The end of the T-wave was determined via the tangent method. QT intervals vary with heart rate, and therefore must be corrected for heart rate. QT intervals were corrected using the Fridericia (QTF) method. Maximum QTF is the longest QTF measured following ibutilide at any time point. | Within 8 hours following ibutilide administration | |
Primary | Maximum Percent Change From Pretreatment Value in QTF Following Ibutilide 0.003 mg/kg | QT interval is an ECG measure of ventricular repolarization. Prolonged QT interval is a marker of increased risk of the ventricular arrhythmia known as torsades de pointes, which can cause sudden cardiac death. Three 12-lead ECGs were obtained ~ 1 minute apart immediately at the end of the ibutilide infusion and at 5, 10, 15, 20, 30, and 45 minutes and 1, 2, 4, 6, and 8 hours post-infusion. QT intervals were measured from ECG lead II by one investigator (E.T.M.) who was blinded to the subjects' assigned treatment phases. QT intervals were measured using computerized high-resolution electronic calipers. QT and RR intervals at each time point were averaged over 3 consecutive complexes. The end of the T-wave was determined via the tangent method. QT intervals were corrected using the Fridericia (QTF) method. | Within 8 hours of ibutilide administration | |
Secondary | Area Under the QTF Versus Time Curve for 0-1 Hour Following Ibutilide 0.003 mg/kg | Prolonged QT interval is a marker of increased risk of the ventricular arrhythmia known as torsades de pointes, which can cause sudden cardiac death. Three 12-lead ECGs were obtained ~ 1 minute apart immediately at the end of the ibutilide infusion and at 5, 10, 15, 20, 30, and 45 minutes and 1, 2, 4, 6, and 8 hours post-infusion. QT intervals were measured from ECG lead II by one investigator (E.T.M.) who was blinded to the subjects' assigned treatment phases. QT intervals were measured using computerized high-resolution electronic calipers. QT and RR intervals at each time point were averaged over 3 consecutive complexes. The end of the T-wave was determined via the tangent method. Area under the QTF curve was calculated using the trapezoidal rule and reflects overall QTF interval "exposure" over time. | 1 hour following ibutilide administration | |
Secondary | Number of Participants With Adverse Effects Associated With Testosterone, Progesterone and Placebo | Adverse effects were assessed by study investigators using telephone calls during the 7-day treatment period in each phase, as well as by asking participants about adverse effects on ibutilide administration days | During 7 day administration periods |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 | |
Completed |
NCT01648205 -
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
|
Phase 2 | |
Recruiting |
NCT06087367 -
Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
|
||
Recruiting |
NCT04675788 -
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
|
Phase 4 | |
Completed |
NCT05759962 -
Phase 1 Study of LQT-1213 in Healthy Adults
|
Phase 1 | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Terminated |
NCT02439645 -
A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
|
||
Recruiting |
NCT00221832 -
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
|
N/A | |
Completed |
NCT04706104 -
QT Measurement Techniques and Anesthesia Management
|
||
Recruiting |
NCT04336644 -
Continuous Versus Intermittent cARdiac Electrical moNitorinG
|
N/A | |
Recruiting |
NCT02814981 -
Hydroxyzine and Risk of Prolongation of QT Interval
|
N/A | |
Completed |
NCT02425189 -
The Canadian National Long QT Syndrome Registry
|
||
Completed |
NCT02876380 -
Prospective Identification of Long QT Syndrome in Fetal Life
|
||
Completed |
NCT00399412 -
ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
|
N/A | |
Completed |
NCT03182777 -
Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
|
N/A | |
Completed |
NCT02441829 -
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
|
Phase 1 | |
Completed |
NCT01849003 -
Study of the Effect of GS-6615 in Subjects With LQT-3
|
Phase 1 | |
Completed |
NCT00316459 -
Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00292032 -
Registry of Unexplained Cardiac Arrest
|
||
Recruiting |
NCT05348564 -
Comparing Direct vs Indirect Methods for Cascade Screening
|
N/A |